Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 9 | 10 | 12 | 13 | 15 | 1 | 3 | 5 | 7 | 9 | 11 | - | |||||
Cash | - | - | - | - | - | - | - | - | - | - | 11 | 14 | |||||
Assets Current | |||||||||||||||||
Assets Current | 9 | 11 | 12 | 14 | 15 | 2 | 4 | 5 | 7 | - | 12 | - | |||||
Grants Receivable | - | - | - | - | 0 | 0 | - | - | - | - | - | - | |||||
Prepaid Expense Current | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |||||
Assets Noncurrent | |||||||||||||||||
Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | - | - | - | |||||
Assets | 9 | 11 | 12 | 14 | 16 | 2 | 4 | 6 | 8 | 9 | 12 | 14 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Accounts Payable Current | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | |||||
Liabilities Current | |||||||||||||||||
Accrued Liabilities Current | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | |||||
Liabilities | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Stockholders Equity | |||||||||||||||||
Additional Paid In Capital | 86 | 86 | 86 | 85 | 85 | 69 | 69 | 69 | 69 | 68 | 68 | 68 | |||||
Stockholders Equity | 8 | 10 | 12 | 13 | 15 | 2 | 4 | 5 | 6 | 8 | 11 | 13 | |||||
Retained Earnings Accumulated Deficit | -78 | -76 | -74 | -72 | -70 | -68 | -65 | -64 | -62 | -60 | -57 | -55 | |||||
Liabilities And Stockholders Equity | 9 | 11 | 12 | 14 | 16 | 2 | 4 | 6 | 8 | 9 | 12 | 14 | |||||
Preferred Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Preferred Stock Shares Authorized | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Common Stock Shares Authorized | 75 | 75 | 75 | 50 | 50 | 50 | 50 | 50 | 40 | 40 | 40 | 40 | |||||
Common Stock Shares Issued | 41 | 41 | 41 | 41 | 41 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | |||||
Shares Outstanding | 41 | 41 | 41 | 41 | 41 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.64% | -52.32% | -55.70% | -4.21% | 57.89% | -3.16% | - | - | - | - | - | - |
| 2025 | -6.77% | 6.45% | -0.90% | -19.55% | -23.31% | -13.53% | 10.77% | 72.31% | 192.31% | 13.64% | -2.69% | -10.33% |
| 2024 | 9.91% | 13.21% | 20.75% | 14.34% | 7.75% | 14.34% | -8.05% | 9.75% | -15.25% | 6.00% | -14.16% | -24.32% |
| 2023 | - | - | - | - | - | - | 7.96% | 1.08% | -5.63% | -25.00% | -34.45% | -28.96% |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 50+ calculated metrics
Subscribe to unlock 17+ years of data and 50+ calculated metrics
Performance and Valuation Metrics
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Anebulo Pharmaceuticals, Inc. (ANEB) — SEC Financial Statements & Analysis
Anebulo Pharmaceuticals, Inc. (ANEB) is a pharmaceutical preparations company, incorporated in DE. Anebulo Pharmaceuticals, Inc. trades on Nasdaq as: ANEB. Based on its latest SEC filing (Form 10-Q, period ending 2025-12-31), Anebulo Pharmaceuticals, Inc. reported a Price-to-Book (P/B) ratio of 5.23 (TTM), at a market cap of $41.50M. Figures below are sourced from SEC EDGAR, as-filed.
- P/B TTM
- 5.23
- Market Cap
- $41.50M
Data as of 2025-12-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Anebulo Pharmaceuticals, Inc. in?
Anebulo Pharmaceuticals, Inc. (ANEB) operates in the Pharmaceutical Preparations industry.
What is ANEB's market cap?
Anebulo Pharmaceuticals, Inc. (ANEB) has a market capitalization of $41.50M as of 2025-12-31.
What exchange does ANEB trade on?
Anebulo Pharmaceuticals, Inc. (ANEB) trades on the Nasdaq.
Where is Anebulo Pharmaceuticals, Inc. incorporated?
Anebulo Pharmaceuticals, Inc. is incorporated in DE.